Kona Medical, a Bellevue, Wash., and Menlo Park, Calif.-based developer of treatments for hypertension, completed a $10m Series D financing round.
Morningside Group was the sole investor.
The company intends to use the funds for the China market.
Led by Michael Gertner, MD, founder and CEO, Kona Medical is developing the Surround Sound® Renal Denervation System, which utilizes ultrasound, delivered from outside the body, to treat nerves leading to and from the kidney.
It is in an investigational stage and is not yet for sale or approved by the US Food and Drug Administration.